LEADER 04028nam 2200541 450 001 9910815061603321 005 20230803212914.0 010 $a92-4-069390-4 035 $a(CKB)3710000000370193 035 $a(EBL)1975017 035 $a(SSID)ssj0001668409 035 $a(PQKBManifestationID)16459599 035 $a(PQKBTitleCode)TC0001668409 035 $a(PQKBWorkID)15003950 035 $a(PQKB)10903187 035 $a(MiAaPQ)EBC1975017 035 $a(Au-PeEL)EBL1975017 035 $a(OCoLC)904517812 035 $a(EXLCZ)993710000000370193 100 $a20220518d2014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGuidelines for the screening, care and treatment of persons with hepatitis C infection $eApril 14 /$fWorld Health Organization 210 1$aGeneva, Switzerland :$cWorld Health Organization,$d[2014] 210 4$dİ2014 215 $a1 online resource (121 p.) 300 $aDescription based upon print version of record. 311 $a92-4-154875-4 320 $aIncludes bibliographical references. 327 $aCover; CONTENTS; ACKNOWLEDGEMENTS; ABBREVIATIONS AND ACRONYMS; GLOSSARY OF TERMS; EXECUTIVE SUMMARY; 1. SCOPE AND OBJECTIVES; 2. BACKGROUND; 2.1 Epidemiology of hepatitis C; 2.1.1 Routes of transmission; 2.1.2 Coinfections; 2.2 Hepatitis C virus; 2.3 Natural history of HCV infection; 2.4 Prevention of HCV infection; 2.5 Screening for HCV infection; 2.6 Care of patients with HCV infection; 2.7 Treatment of patients with HCV infection; 2.8 Cost-effectiveness of treatment; 3. GUIDING PRINCIPLES; 3.1 Human rights; 3.2 Access to health care; 3.3 Service provision; 3.4 Integrated health care 327 $a4. METHODS5. RECOMMENDATIONS ON SCREENING; 5.1 Screening to identify persons with HCV infection; 5.2 When to confirm a diagnosis of chronic HCV infection; 6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV; 6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake; 6.2 Assessing the degree of liver fibrosis and cirrhosis; 7. RECOMMENDATIONS ON TREATMENT; 7.1 Assessment for HCV treatment; 7.2 Treatment with pegylated interferon and ribavirin; 7.3 Treatment with telaprevir or boceprevir 327 $a7.4 Introduction to recommendations concerning sofosbuvir and simeprevir7.5 Treatment with sofosbuvir; 7.6 Treatment with simeprevir; 8. CLINICAL CONSIDERATIONS; 8.1 Monitoring for toxicity; 8.2 Dose modification; 8.3 Monitoring for efficacy; 9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS; 9.1 People who inject drugs; 9.2 Persons with HIV and HCV coinfection; 9.3 Children and adolescents; 9.4 Persons with liver cirrhosis; 9.5 Persons with HBV and TB coinfection; 9.6 Persons with renal impairment; 10. OPERATIONAL AND IMPLEMENTATION ISSUES; 10.1 Service planning; 10.2 Service delivery 327 $a10.3 Future considerations10.4 Dissemination, monitoring and implementation of the Guidelines; 11. REFERENCES 330 $aThese are the first WHO guidelines on the screening care and treatment ofpersons with HCV infection. They are intended to complement existing guidanceon the primary prevention of HCV and other bloodborne viruses by improvingblood and injection safety and health care for people who inject drugs (PWID)and other vulnerable groups including those living with HIV (see section 2.4 forrelated WHO guidelines).These guidelines are primarily targeted at policy-makers in ministries of healthworking in low- and middle-income countries who formulate country-specifictreatment guidelines and who plan infe 606 $aHepatitis C$xDiagnosis 615 0$aHepatitis C$xDiagnosis. 676 $a616.3623 712 02$aWorld Health Organization. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910815061603321 996 $aGuidelines for the screening, care and treatment of persons with hepatitis C infection$93935060 997 $aUNINA